ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.97−0.03 (-3.47%)
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
ALX Oncology cash
Cash and short-term investments held at the end of each period.
ALX Oncology's cash was $138.23M at Jun 30, 2026. For fiscal 2025 it was $44.79M, down 65.0% from the year before. The highest annual figure on record is $434.22M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.79M | -65.0% |
| FY2024 | Dec 31, 2024 | $127.82M | -30.1% |
| FY2023 | Dec 31, 2023 | $182.74M | -31.4% |
| FY2022 | Dec 31, 2022 | $266.27M | -26.8% |
| FY2021 | Dec 31, 2021 | $363.67M | -16.2% |
| FY2020 | Dec 31, 2020 | $434.22M | +4715.6% |
| FY2019 | Dec 31, 2019 | $9.02M | +9.1% |
| FY2018 | Dec 31, 2018 | $8.26M | -62.6% |
| FY2017 | Dec 31, 2017 | $22.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $138.23M | +74.3% |
| Q1 FY2026 | Mar 31, 2026 | $140.32M | +43.4% |
| Q4 FY2025 | Dec 31, 2025 | $44.79M | -65.0% |
| Q3 FY2025 | Sep 30, 2025 | $60.63M | -59.2% |
| Q2 FY2025 | Jun 30, 2025 | $79.31M | -49.4% |
| Q1 FY2025 | Mar 31, 2025 | $97.83M | -37.9% |
| Q4 FY2024 | Dec 31, 2024 | $127.82M | -30.1% |
| Q3 FY2024 | Sep 30, 2024 | $148.57M | -21.8% |
| Q2 FY2024 | Jun 30, 2024 | $156.72M | -26.4% |
| Q1 FY2024 | Mar 31, 2024 | $157.44M | -30.9% |
| Q4 FY2023 | Dec 31, 2023 | $182.74M | -31.4% |
| Q3 FY2023 | Sep 30, 2023 | $190.01M | -33.3% |
| Q2 FY2023 | Jun 30, 2023 | $212.84M | -32.1% |
| Q1 FY2023 | Mar 31, 2023 | $227.94M | -28.0% |
| Q4 FY2022 | Dec 31, 2022 | $266.27M | -26.8% |
| Q3 FY2022 | Sep 30, 2022 | $284.91M | -26.0% |
| Q2 FY2022 | Jun 30, 2022 | $313.37M | -23.6% |
| Q1 FY2022 | Mar 31, 2022 | $316.60M | -26.3% |
| Q4 FY2021 | Dec 31, 2021 | $363.67M | -16.2% |
| Q3 FY2021 | Sep 30, 2021 | $385.15M | +48.4% |
| Q2 FY2021 | Jun 30, 2021 | $409.96M | +317.9% |
| Q1 FY2021 | Mar 31, 2021 | $429.86M | +309.2% |
| Q4 FY2020 | Dec 31, 2020 | $434.22M | +4715.6% |
| Q3 FY2020 | Sep 30, 2020 | $259.48M | +4296.5% |
| Q2 FY2020 | Jun 30, 2020 | $98.10M | +979.5% |
| Q1 FY2020 | Mar 31, 2020 | $105.04M | +1171.3% |
| Q4 FY2019 | Dec 31, 2019 | $9.02M | -59.2% |
| Q3 FY2019 | Sep 30, 2019 | $5.90M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.09M | – |
| Q4 FY2018 | Dec 31, 2018 | $8.26M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.10M | – |
See a number that looks wrong?